Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

160.13 +0.27 (+0.17%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
3 Dow Stocks You Can Confidently Buy Now and Hold Forever
Three highly profitable, time-tested Dow components have the necessary tools to make their patient shareholders notably richer. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
Johnson & Johnson to Participate in the Leerink Global Biopharma Conference
From Johnson & Johnson
Via Business Wire
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
These incredible businesses have long histories of successes behind them, and more to come. 
Via The Motley Fool
Passive Income Powerhouses: 7 Blue-Chip Stocks to Own Now
If you are looking to build wealth through dividend income, here are the passive income blue-chip stocks to buy. 
Via InvestorPlace
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Is Johnson & Johnson Stock a Buy Now?
Don't overlook this boring company's stellar reliability. 
Via The Motley Fool
3 High Yield Dividend Aristocrats To Buy Now
The Dividend Aristocrats have increased their dividends every year for at least 25 years in a row. 
Via Talk Markets
DNA Sequencing Kit Provider Illumina's Q4 Earnings Edge Above Street Estimates, Works To Resolve GRAIL Quickly
Illumina exceeds Q4 2023 expectations with $1.12 billion sales, up 4% YoY. CEO Jacob Thaysen anticipates growth and outlines strategic priorities for 2024. 
Via Benzinga
Dividend Dynasties: 3 Stocks Set to Deliver Consistent Income
Unlock reliable cash flow with these Dividend Aristocrats. They're elite S&P 500 dividend stocks raising payouts for 25+ years. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
Via Benzinga
3 Dividend Stocks to Cling to This Year
Build a retirement portfolio with these three dividend stocks to enjoy passive income and capital growth over the years. 
Via InvestorPlace
Topics Retirement
Exposures Pension
The Watch List: Is Warren Buffett Still Selling These 3 Stocks?
Just because Warren Buffett marked these as stocks to sell doesn't always mean investors need to walk lockstep with him. 
Via InvestorPlace
Analyzing NYSE:JNJ's Dividend Potential.
Is JOHNSON & JOHNSON (NYSE:JNJ) a Good Fit for Dividend Investing? 
Via Chartmill
Is Johnson & Johnson a Good Dividend Stock to Buy Now?
The healthcare conglomerate has been raising its dividend payout since Kennedy was president, but there have been some recent changes. 
Via The Motley Fool
7 Dividend Stocks Worth Holding for the Long Haul
These dividend stocks are worth holding for the long term both for upside and income production that can add up quickly. 
Via InvestorPlace
The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024
Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements. 
Via InvestorPlace
New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies
Johnson & Johnson's nipocalimab shows promise in Phase 3 VIVACITY for gMG & Phase 2 DAHLIAS for SjD. FDA-approved Vyvgart Hytrulo for gMG. 
Via Benzinga
Verizon, Walgreens, 3M: 3 high-yield Dow stocks to buy now?
Dow's high-yielding trio, Verizon, Walgreens, and 3M face challenges, which are reflected in their stock-price declines. 
Via MarketBeat
Topics Stocks
Exposures US Equities
2 Healthcare Dividend Kings to Buy and Hold Forever
It's going to take a lot to interrupt these companies' streaks. 
Via The Motley Fool
7 Dividend Stocks That Pay Me More Than $500 Per Month
These stocks pay safe, reliable, and growing dividends. 
Via The Motley Fool
Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
From Johnson & Johnson
Via Business Wire
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000
FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address... 
Via Benzinga
Exposures Product Safety
The 7 Best Blue-Chip Stocks to Invest In for Big Gains in 2024
Investors looking for reliable stocks that can be expected to continuously rise and provide strong returns should consider these names. 
Via InvestorPlace
4 med tech stocks with improving prognosis for 2024
MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025. 
Via MarketBeat
Exposures COVID-19
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot
Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding. 
Via InvestorPlace
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
Will Novo Nordisk Be a $1 Trillion Company by 2030?
Novo Nordisk's market cap has ballooned thanks to the overwhelming success of its Ozempic, Wegovy, and Rybelsus medications. 
Via The Motley Fool
Wall Street's Greatest Dividend Stock Just Made History Again, and 99% of Investors Probably Don't Realize It Exists
This virtually unknown company has been paying a consecutive dividend to its investors for more than 200 years. 
Via The Motley Fool
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.